KRAS and neoplasm: Despite initial clinical efficacy, patients may experience progression on osimertinib due to factors such as loss of the T790M mutation, acquisition of the C797S mutation, mutations in other oncogenes such as KRAS, gene fusions, MET amplification, or transformation of the tumor to small-cell lung cancer [10].